This book presents the latest knowledge on the roles of progranulin (PGRN) in normal physiology and pathology and explores the emerging significance of PGRN as a therapeutic target and biomarker in various CNS disorders, including frontotemporal lobe degeneration and other neurodegenerative diseases. Following initial recognition of the importance of PGRN in sexual differentiation of the developing brain and adult neurogenesis, it was subsequently discovered that PGRN acts as a chaperone of lysosomal enzymes and plays a crucial role in maintaining cellular protein homeostasis. It has also been…mehr
This book presents the latest knowledge on the roles of progranulin (PGRN) in normal physiology and pathology and explores the emerging significance of PGRN as a therapeutic target and biomarker in various CNS disorders, including frontotemporal lobe degeneration and other neurodegenerative diseases. Following initial recognition of the importance of PGRN in sexual differentiation of the developing brain and adult neurogenesis, it was subsequently discovered that PGRN acts as a chaperone of lysosomal enzymes and plays a crucial role in maintaining cellular protein homeostasis. It has also been found that sex steroids modulate the expression of PGRN and its trophic effects in the developing CNS and that PGRN directly or indirectly influences neural stem and progenitor cells. Against this background, deeper understanding of the molecular and functional properties of PGRN would provide fresh impetus for the development of mechanism-based therapeutic approaches formultiple disorders. Medications targeting the recovery of lysosomal function appear to hold particular promise in patients with neurodegenerative diseases resulting from PGRN insufficiency. In examining multiple aspects of this fascinating field, the book will be of high value for researchers and graduate students.
Hideaki Hara, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Japan Masato Hosokawa, Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, Japan Shinsuke Nakamura, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Japan Takayoshi Shimohata, Department of Neurology and Geriatrics, Gifu University Graduate School of Medicine, Japan Masugi Nishihara, Department of Veterinary Physiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Japan
Inhaltsangabe
Chapter 1. Molecular and Functional Properties of Progranulin.- Chapter 2. Progranulin as a biomarker for neurodegenerative diseases.- Chapter 3. PGRN and FTLD.- Chapter 4. PGRN and neurodegenerative diseases other than FTLD.- Chapter 5. Progranulin Regulations of Lysosomal Homeostasis and its Involvement in Neurodegenerative Diseases.- Chapter 6. Molecular and Functional Properties of Progranulin.- Chapter 7. PGRN and neuroinflammation.- Chapter 8. Neural Stem/Progenitor Cells and Progranulin.- Chapter 9. Generation and phenotyping of progranulin-deficient mice.- Chapter 10. Pleiotropic protective effects of progranulin in the treatment of ischemic stroke.- Chapter 11. New therapeutic approaches against ocular diseases.
Chapter 1. Molecular and Functional Properties of Progranulin.- Chapter 2. Progranulin as a biomarker for neurodegenerative diseases.- Chapter 3. PGRN and FTLD.- Chapter 4. PGRN and neurodegenerative diseases other than FTLD.- Chapter 5. Progranulin Regulations of Lysosomal Homeostasis and its Involvement in Neurodegenerative Diseases.- Chapter 6. Molecular and Functional Properties of Progranulin.- Chapter 7. PGRN and neuroinflammation.- Chapter 8. Neural Stem/Progenitor Cells and Progranulin.- Chapter 9. Generation and phenotyping of progranulin-deficient mice.- Chapter 10. Pleiotropic protective effects of progranulin in the treatment of ischemic stroke.- Chapter 11. New therapeutic approaches against ocular diseases.
Chapter 1. Molecular and Functional Properties of Progranulin.- Chapter 2. Progranulin as a biomarker for neurodegenerative diseases.- Chapter 3. PGRN and FTLD.- Chapter 4. PGRN and neurodegenerative diseases other than FTLD.- Chapter 5. Progranulin Regulations of Lysosomal Homeostasis and its Involvement in Neurodegenerative Diseases.- Chapter 6. Molecular and Functional Properties of Progranulin.- Chapter 7. PGRN and neuroinflammation.- Chapter 8. Neural Stem/Progenitor Cells and Progranulin.- Chapter 9. Generation and phenotyping of progranulin-deficient mice.- Chapter 10. Pleiotropic protective effects of progranulin in the treatment of ischemic stroke.- Chapter 11. New therapeutic approaches against ocular diseases.
Chapter 1. Molecular and Functional Properties of Progranulin.- Chapter 2. Progranulin as a biomarker for neurodegenerative diseases.- Chapter 3. PGRN and FTLD.- Chapter 4. PGRN and neurodegenerative diseases other than FTLD.- Chapter 5. Progranulin Regulations of Lysosomal Homeostasis and its Involvement in Neurodegenerative Diseases.- Chapter 6. Molecular and Functional Properties of Progranulin.- Chapter 7. PGRN and neuroinflammation.- Chapter 8. Neural Stem/Progenitor Cells and Progranulin.- Chapter 9. Generation and phenotyping of progranulin-deficient mice.- Chapter 10. Pleiotropic protective effects of progranulin in the treatment of ischemic stroke.- Chapter 11. New therapeutic approaches against ocular diseases.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497